Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)

Fig. 1

In PA-induced insulin resistance model, the expression of PCSK9, LDLR, and GCK after polydatin treatment. a Insulin resistant HepG2 cells were incubated with polydatin of the indicated concentrations for 24 h and measured by MTT assay. b LDLR and GCK protein expression with polydation treatments in 5, 10, 20, 40 μM for 24 h. c LDLR and GCK protein expression with polydation treatments in 20 μM for different time. d PCSK9, LDLR, and GCK expression with polydatin treatment in 20 μM for 24 h. All experiments were performed with polydatin (indicated concentration) pretreatment for 2 h, and then incubated with 0.25 mM of PA for another 24 h to induce insulin resistance for more than three times. Intensities were quantified and normalized against the level of α-tubulin abundance in corresponding BSA-treated cells. $ p < 0.05 vs. Con; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. LDLR levels in the control group (Con); ^ p < 0.05 and ^^ p < 0.01 vs. GCK levels in the control group (Con); ### p < 0.001 vs. IR group

Back to article page